Previous studies have shown that many EGFR TKIs, including erlotinib (23, 25, 26), gefitinib (27), cetuximab (15, 16) and icotinib (28) are effective and safe for patients with esophageal squamous cell carcinoma (ESCC). This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.